RAD51D and breast cancer: Question 5: what breast surveillance should be offered to RAD51C and RAD51D carriers with a lifetime BC risk of 17%–30% (National institute for Health and Care Excellence (NICE) moderate-risk category)? and question 6: what breast surveillance should be offered to RAD51C and RAD51D carriers with a lifetime BC risk of >30% but <40% (NICE high-risk category)